Literature DB >> 31882173

The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus.

Daniel M Breitkopf1, Vera Jankowski2, Kim Ohl3, Juliane Hermann2, Daniela Hermert1, Klaus Tenbrock3, Xiyang Liu1, Ina V Martin1, Jialin Wang4, Fabian Groll1, Elisabeth Gröne5, Jürgen Floege1, Tammo Ostendorf1, Thomas Rauen6, Ute Raffetseder7.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease and lupus nephritis is a major risk factor for morbidity and mortality. Notch-3 signaling induced by membrane-bound or soluble ligands such as YB-1 constitutes an evolutionarily conserved pathway that determines major decisions in cell fate. Mass spectrometry of extracellular YB-1 in sera from patients with SLE and lupus-prone mice revealed specific post-translational guanidinylation of two lysine residues within the highly conserved cold-shock domain of YB-1 (YB-1-G). These modifications highly correlated with SLE disease activity, especially in patients with lupus nephritis and resulted in enhanced activation of Notch-3 signaling in T lymphocytes. The importance of YB-1:Notch-3 interaction in T cells was further evidenced by increased interleukin (Il)10 expression following YB-1-G stimulation and detection of both, YB-1-G and Notch-3, in kidneys of MRL.lpr mice by mass spectrometry imaging. Notch-3 expression and activation was significantly up-regulated in kidneys of 20-week-old MRL.lpr mice. Notably, lupus-prone mice with constitutional Notch-3 depletion (B6.Faslpr/lprNotch3-/-) exhibited an aggravated lupus phenotype with significantly increased mortality, enlarged lymphoid organs and aggravated nephritis. Additionally, these mice displayed fewer regulatory T cells and reduced amounts of anti-inflammatory IL-10. Thus, our results indicate that the YB-1:Notch-3 axis exerts protective effects in SLE and that Notch-3 deficiency exacerbates the SLE phenotype.
Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Notch-3; SLE; YB-1; lupus; lupus nephritis

Mesh:

Substances:

Year:  2019        PMID: 31882173     DOI: 10.1016/j.kint.2019.09.031

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Fibrosis and Immune Cell Infiltration Are Separate Events Regulated by Cell-Specific Receptor Notch3 Expression.

Authors:  Sabine Brandt; Tobias M Ballhause; Anja Bernhardt; Annika Becker; Delia Salaru; Hien Minh Le-Deffge; Alexander Fehr; Yan Fu; Lars Philipsen; Sonja Djudjaj; Andreas J Müller; Rafael Kramann; Mahmoud Ibrahim; Robert Geffers; Chris Siebel; Berend Isermann; Florian H Heidel; Jonathan A Lindquist; Peter R Mertens
Journal:  J Am Soc Nephrol       Date:  2020-08-28       Impact factor: 10.121

2.  Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury.

Authors:  Stefan J Schunk; Juliane Hermann; Tamim Sarakpi; Sarah Triem; Michaela Lellig; Eunsil Hahm; Stephen Zewinger; David Schmit; Ellen Becker; Julia Möllmann; Michael Lehrke; Rafael Kramann; Peter Boor; Peter Lipp; Ulrich Laufs; Winfried März; Jochen Reiser; Joachim Jankowski; Danilo Fliser; Thimoteus Speer; Vera Jankowski
Journal:  J Am Soc Nephrol       Date:  2021-09-29       Impact factor: 10.121

3.  Exploration of immune response mechanisms in cadmium and copper co-exposed juvenile golden cuttlefish (Sepia esculenta) based on transcriptome profiling.

Authors:  Xiaokai Bao; Weijun Wang; Xipan Chen; Yanwei Feng; Xiaohui Xu; Guohua Sun; Bin Li; Xiumei Liu; Zan Li; Jianmin Yang
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 4.  The Role of Notch3 Signaling in Kidney Disease.

Authors:  Cheng Yuan; Lihua Ni; Changjiang Zhang; Xiaoyan Wu
Journal:  Oxid Med Cell Longev       Date:  2020-10-22       Impact factor: 6.543

5.  YBX1 promotes tumor progression via the PI3K/AKT signaling pathway in laryngeal squamous cell carcinoma.

Authors:  Jing Zhao; Pu Zhang; Xin Wang
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.